搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
1 天
Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
2 天
Gilead Sciences Unusual Options Activity For September 20
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
4 天
on MSN
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...
Zacks.com on MSN
3 天
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...
FiercePharma
2 天
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
4 天
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.
5 天
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...
Zacks.com on MSN
5 天
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
FierceBiotech
50 分钟
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
The New York Times
6 天
Gilead Sciences Inc
By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...
FiercePharma
3 天
Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈